ScripPfizer stands to expand the addressable market for its hemophilia A and B drug Hympavzi (marstacimab-hncq) with Phase III data showing it is effective in patients with clotting factor inhibitors along
ScripSangamo Therapeutics’ efforts to secure a partnership for ST-920 (isaralgagene civoparvovec), its gene therapy for Fabry disease, should get easier now that the biotech has positive pivotal data suppo
ScripAtsena Therapeutics thinks it can be a success story in the gene therapy field, where some companies have recently stumbled, with the closure of a funding round that it plans to use especially for its
ScripWho: Sangamo Therapeutics/Eli Lilly What: Lilly signed a deal with Sangamo to license the gene therapy company’s STAC-BBB adeno-associated viral vector capsid for up to five potential neurological